Keynotes

Dr Jorge Cardoso

Dr. Jorge Cardoso leads a research portfolio on big data analytics, quantitative radiology and value based healthcare. He is also the CTO of the new InnovateUK-funded “London Medical Imaging and AI Centre for Value Based Healthcare”, where he is leading the development of a software platform and associated computing infrastructure to enable data aggregation, machine learning and actionable analytics at scale across the three King’s Health Partners trusts. He has more than 12 years expertise in advanced image analysis, big data, and artificial intelligence, and co-leads the development of NiftyNet, a deep-learning platform for artificial intelligence in medical imaging. He is also a founder and CSO of BrainMiner, a medtech startup aiming to bring quantitative biomarkers and predictive models to neurological care.


Duygu Tosun-Turgut, PhD, is an Associate Professor of Radiology and Biomedical Imaging at the University of California – San Francisco and Director of the Medical Imaging Informatics and Artificial Intelligence at the San Francisco Veterans Affairs Medical Center. Dr. Tosun obtained her BSc in Electrical and Electronic Engineering from Bilkent University, Turkey in 1999, and she received her MSE in Electrical and Computer Engineering from The Johns Hopkins University, Maryland in 2001. In 2003, she completed her MA in Mathematics from The Johns Hopkins University, and she earned her PhD in Electrical and Computer Engineering from The Johns Hopkins University in 2005, followed by a postdoctoral fellowship in Neurology from the University of California, Los Angeles in 2008. Her research is in the field of neuroimaging in aging, neurodegenerative diseases, and psychiatric disorders and aims to apply advanced imaging technology to identify multi-disciplinary and multi-modality biomarkers to detect the pathophysiological progression of neuropathologies before they cause irreversible damage to the brain. Dr. Tosun-Turgut aims to develop validated imaging markers, potentially providing a means of monitoring the efficacy and regional specificity of drug therapy for neurodegenerative diseases. This will have a broad use in early diagnosis, facilitating initiation of prevention strategies in those at risk, and boost the power of drug therapy trials by selecting those at greatest risk of neurodegenerative diseases. Dr. Tosun-Turgut’s research has been funded by the National Institutes of Health, California Department of Public Health, Department of Defense, Alzheimer’s Association, Michael J Fox Foundation, and through various pharmaceutical collaborations.